Abstract
Aim. A wide range of clinical phenomena have been reported with dose reduction or drug discontinuation of Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs). In 2015, a new classification of SSRIs/ SNRIs withdrawal (i.e., new withdrawal symptoms, rebound symptoms withdrawal, persistent post-withdrawal disorders) was outlined on the basis of the literature and clinical observations. A semistructured clinical interview, the Diagnostic clinical Interview for Drug Withdrawal 1-New Symptoms of SSRI and SNRI (DID-W1), was developed for identifying and differentiating such syndromes. Its inter-rater reliability has been tested. Methods. Seventeen consecutive outpatients with a history of SSRI or SNRI dose reduction or discontinuation were assessed independently by 2 clinicians at different times during the same day. Percent agreement, Cohen's kappa, and the squared correlation coefficient were used to measure inter-rater reliability. Results. The percent agreement for the whole interview was 97.06%, the Cohen's kappa 0.85 (95% CI of 0.61-1.08), the squared correlation coefficient 0.72. Discussion and conclusions. The kappa values indicated excellent inter-rater agreement. Validity evaluation and comparison with other instruments need to be performed. The DID-W1 may help diagnosing the clinical phenomena related to SSRI and SNRI discontinuation, their differentiation from relapse, and the potential iatrogenic origin of psychiatric symptoms in clinical practice.
Original language | English |
---|---|
Pages (from-to) | 95-99 |
Number of pages | 5 |
Journal | Rivista Di Psichiatria |
Volume | 53 |
Issue number | 2 |
DOIs | |
Publication status | Published - 1 Mar 2018 |
Keywords
- withdrawal
- selective serotonin reuptake inhibitor
- serotonin norepinephrine reuptake inhibitor
- interview
- reliability
- iatrogenic comorbidity
- DISCONTINUATION SYNDROME
- ANTIDEPRESSANT DRUGS
- IATROGENIC-COMORBIDITY
- PANIC DISORDER
- SCALE
- PHARMACOPSYCHOLOGY
- DEPRESSION
- PAROXETINE
- PSYCHOSIS
- SAFETY